Pfizer's Infliximab Biosimilar Approved In US But Won't Launch Against Inflectra
Executive Summary
Ixifi (infliximab-qbtx), which references Janssen's Remicade, marks first US approval of a biosimilar developed entirely by Pfizer; big pharma says it is not currently planning to launch Ixifi because it remains "committed" to marketing Celltrion's Inflectra.
You may also be interested in...
10 Things For Pfizer's New CEO To Worry About
Albert Bourla will face opportunities and potential pitfalls.
EU CHMP Finalizes Outstanding Issues On Aimovig And Symproic
EU regulators meeting in London are finalizing the outstanding questions they have for companies whose products are approaching the final stages of the approval process.
EU CHMP Finalizes Outstanding Issues On Aimovig And Symproic
EU regulators meeting in London are finalizing the outstanding questions they have for companies whose products are approaching the final stages of the approval process.